S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.60%)
CGC   17.64 (+15.14%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
BAC   32.69 (-0.76%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.60%)
CGC   17.64 (+15.14%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
BAC   32.69 (-0.76%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.60%)
CGC   17.64 (+15.14%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
BAC   32.69 (-0.76%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.60%)
CGC   17.64 (+15.14%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
BAC   32.69 (-0.76%)
DIS   146.93 (-0.98%)
Log in

ImmunoCellular Therapeutics Stock Price, Forecast & Analysis (NYSEAMERICAN:IMUC)

$0.04
-0.01 (-19.80 %)
(As of 11/20/2019 04:00 PM ET)
Today's Range
$0.04
Now: $0.04
$0.05
50-Day Range N/A
52-Week Range
$0.01
Now: $0.04
$0.05
Volume76,195 shs
Average Volume133,738 shs
Market Capitalization$1.70 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its products include ICT-107, a dendritic cell (DC) immunotherapy for the treatment of diagnosed glioblastoma multiforme (GBM); ICT-140, a DC-based immunotherapy targets tumor associated antigens on ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs to treat recurrent GBM and other solid tumor cancers. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNYSEAMERICAN:IMUC
CUSIP45253610
CIKN/A
Phone+1-818-2642300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$1.70 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IMUC News and Ratings via Email

Sign-up to receive the latest news and ratings for IMUC and its competitors with MarketBeat's FREE daily newsletter.


ImmunoCellular Therapeutics (NYSEAMERICAN:IMUC) Frequently Asked Questions

What is ImmunoCellular Therapeutics' stock symbol?

ImmunoCellular Therapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IMUC."

How were ImmunoCellular Therapeutics' earnings last quarter?

ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) announced its quarterly earnings results on Monday, August, 13th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. View ImmunoCellular Therapeutics' Earnings History.

Has ImmunoCellular Therapeutics been receiving favorable news coverage?

Media headlines about IMUC stock have been trending somewhat negative this week, according to InfoTrie. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ImmunoCellular Therapeutics earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for ImmunoCellular Therapeutics.

Who are some of ImmunoCellular Therapeutics' key competitors?

What other stocks do shareholders of ImmunoCellular Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoCellular Therapeutics investors own include Argos Therapeutics (ARGSQ), NightFood (NGTF), SLS International (SLS), Inovio Pharmaceuticals (INO), XOMA (XOMA), NovaBay Pharmaceuticals (NBY), CytRx (CYTR), MannKind (MNKD), Agenus (AGEN) and Novavax (NVAX).

Who are ImmunoCellular Therapeutics' key executives?

ImmunoCellular Therapeutics' management team includes the folowing people:
  • Mr. Gary S. Titus, Chairman & Corp. Sec. (Age 58)
  • Dr. Anthony J. Gringeri, CEO, Pres & Director (Age 65)
  • Dr. John S. Yu, Founder & Director (Age 54)
  • Mr. David E. Fractor, Chief Financial Officer (Age 58)
  • Dr. Steven J. Swanson, Sr. VP of Research (Age 62)

How do I buy shares of ImmunoCellular Therapeutics?

Shares of IMUC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ImmunoCellular Therapeutics' stock price today?

One share of IMUC stock can currently be purchased for approximately $0.04.

How big of a company is ImmunoCellular Therapeutics?

ImmunoCellular Therapeutics has a market capitalization of $1.70 million. View Additional Information About ImmunoCellular Therapeutics.

What is ImmunoCellular Therapeutics' official website?

The official website for ImmunoCellular Therapeutics is http://imuc.com/.

How can I contact ImmunoCellular Therapeutics?

ImmunoCellular Therapeutics' mailing address is 30721 Russell Ranch Rd Ste 140, WESTLAKE VILLAGE, CA 91362-7383, United States. The biotechnology company can be reached via phone at +1-818-2642300.


MarketBeat Community Rating for ImmunoCellular Therapeutics (NYSEAMERICAN IMUC)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  218 (Vote Underperform)
Total Votes:  438
MarketBeat's community ratings are surveys of what our community members think about ImmunoCellular Therapeutics and other stocks. Vote "Outperform" if you believe IMUC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMUC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Featured Article: What Are Treasury Bonds?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel